Clinical trial
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
NCT00255346 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00255346 |
|---|---|
| Title | Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) |
| Official title | Therapy of Myeloid Metaplasia-Myelofibrosis, Atypical Chronic Myeloid or Myelomonocytic Leukemia, C-Kit Positive Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (AML-MDS), Hypereosinophilic Syndrome, Polycythemia Vera, and Mastocytosis With Dasatinib (BMS-354825) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia, Myelodysplastic Syndromes, Agnogenic Myeloid Metaplasia, Myelofibrosis, Hypereosinophilic Syndrome, Polycythemia Vera, Mastocytosis, Leukemia, Myelomonocytic, Chronic |
| Intervention type | Drug |
| Interventions | Dasatinib (BMS-354825) |
| Enrollment | 68 |
| Start date | Nov 15, 2005 |
| Primary completion | Mar 3, 2017 |
| Completion | Mar 3, 2017 |
| First posted | Nov 18, 2005 |
| Last update posted | Dec 30, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: